Injective is making waves in the institutional investment landscape, thanks to its recent listing on the popular financial platform Revolut and the filing of two Exchange-Traded Funds (ETFs) focused on its native token, INJ. According to analysts cited in the report, the outlook is promising.
Injective Listed on Revolut
The recent listing of Injective on Revolut, which boasts over 60 million users, marks a significant milestone for the platform, potentially increasing its user base and trading volume. This exposure is crucial for Injective as it seeks to establish itself in the competitive crypto market.
Canary Capital Files for Staked INJ ETF
In addition to the Revolut listing, Canary Capital has filed for a staked INJ ETF, which aims to provide investors with direct exposure to the spot price of Injective along with its staking rewards, pending regulatory approval. This move is expected to attract more institutional capital into the Injective ecosystem.
21Shares Proposes Injective-Focused ETF
Furthermore, 21Shares has also submitted a proposal for an Injective-focused ETF, further broadening the avenues for institutional access to this innovative network. These initiatives are anticipated to significantly boost the visibility and adoption of Injective within the financial markets.
In a recent address, Japan's Finance Minister highlighted the rising interest in cryptocurrency ETFs as a hedge against inflation, contrasting with Injective's recent institutional developments. For more details, see more.
